Skip to content
Head to head

Bausch Health vs Takeda Pharmaceutical

Side-by-side on the measures that matter, with a plain-English read. Full detail: BHC · TAK

Updated 4 minutes ago

1-year performance, rebased to 100

BHC +34.1%TAK +56.6%
Takeda Pharmaceutical edges it on the scoreable measures. Takeda Pharmaceutical has the highest Quant Rating (88); Takeda Pharmaceutical has done best over the past year (+57%); Takeda Pharmaceutical pays the highest dividend yield.
BHCTAK
Snapshot
Sector----
Last price8.2221.77
Change today-3.97%+1.68%
1-year return+37.0%+57.5%
Market cap$3.08B$69.76B
52-week range4.33 – 9.0413.92 – 22.07
Valuation
P/E (TTM)-3.65311.00
P/E percentile, own 5-yr range57th100th
P/B-2.321.50
Dividend yield0.00%1.44%
Profitability & growth
EPS (TTM)0.42-0.30
Net profit (TTM)$157.19M$-970.94M
Revenue (TTM)$11.11B$4.69T
Provider revenue period date2026-09-292026-09-29
Revenue growth (YoY)+9.7%+6.7%
Gross margin72.6%65.8%
Operating margin28.0%14.3%
Net margin-7.6%0.9%
Free cash flow (TTM)$1.83B$433.95B
Provider cash-flow period date2026-09-292026-09-29
Ownership & sentiment
Institutional ownership64.9%50.7%
Insider activity (12mo)31 buy / 19 sell19 buy / 31 sell
Short interest (% of float)2.0%0.1%
Analyst consensus100% hold (3)100% buy (1)
Analyst price target$9 (+9%)$43 (+97%)
StockVane view
StockVane Quant RatingC (80)C (88)
Company
Employees20,30047,029
Founded20021781

▲ marks the more favourable stock(s) on measures with a clear direction (lower P/E, higher yield, higher Quant Rating, better 1-year return). Analyst consensus counts each covering institution once, at its most recent rating. Not a recommendation. Quant Rating method: Data & Methodology.